Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium

Immune checkpoints have come to the forefront of cancer therapies as a powerful and promising strategy to stimulate antitumor T cell activity. Results from recent preclinical and clinical studies demonstrate how checkpoint inhibition can be utilized to prevent tumor immune evasion and both local and...

Full description

Bibliographic Details
Main Authors: Eileen S. Kim, Jennifer E. Kim, Mira A. Patel, Antonella Mangraviti, Jacob Ruzevick, Michael Lim
Format: Article
Language:English
Published: Hindawi Limited 2016-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2016/4683607
id doaj-95b7bbaf19d2452ba4a2112d50f84d15
record_format Article
spelling doaj-95b7bbaf19d2452ba4a2112d50f84d152020-11-24T22:28:51ZengHindawi LimitedJournal of Immunology Research2314-88612314-71562016-01-01201610.1155/2016/46836074683607Immune Checkpoint Modulators: An Emerging Antiglioma ArmamentariumEileen S. Kim0Jennifer E. Kim1Mira A. Patel2Antonella Mangraviti3Jacob Ruzevick4Michael Lim5Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USADepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USADepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USADepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USADepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USADepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USAImmune checkpoints have come to the forefront of cancer therapies as a powerful and promising strategy to stimulate antitumor T cell activity. Results from recent preclinical and clinical studies demonstrate how checkpoint inhibition can be utilized to prevent tumor immune evasion and both local and systemic immune suppression. This review encompasses the key immune checkpoints that have been found to play a role in tumorigenesis and, more specifically, gliomagenesis. The review will provide an overview of the existing preclinical and clinical data, antitumor efficacy, and clinical applications for each checkpoint with respect to GBM, as well as a summary of combination therapies with chemotherapy and radiation.http://dx.doi.org/10.1155/2016/4683607
collection DOAJ
language English
format Article
sources DOAJ
author Eileen S. Kim
Jennifer E. Kim
Mira A. Patel
Antonella Mangraviti
Jacob Ruzevick
Michael Lim
spellingShingle Eileen S. Kim
Jennifer E. Kim
Mira A. Patel
Antonella Mangraviti
Jacob Ruzevick
Michael Lim
Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium
Journal of Immunology Research
author_facet Eileen S. Kim
Jennifer E. Kim
Mira A. Patel
Antonella Mangraviti
Jacob Ruzevick
Michael Lim
author_sort Eileen S. Kim
title Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium
title_short Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium
title_full Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium
title_fullStr Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium
title_full_unstemmed Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium
title_sort immune checkpoint modulators: an emerging antiglioma armamentarium
publisher Hindawi Limited
series Journal of Immunology Research
issn 2314-8861
2314-7156
publishDate 2016-01-01
description Immune checkpoints have come to the forefront of cancer therapies as a powerful and promising strategy to stimulate antitumor T cell activity. Results from recent preclinical and clinical studies demonstrate how checkpoint inhibition can be utilized to prevent tumor immune evasion and both local and systemic immune suppression. This review encompasses the key immune checkpoints that have been found to play a role in tumorigenesis and, more specifically, gliomagenesis. The review will provide an overview of the existing preclinical and clinical data, antitumor efficacy, and clinical applications for each checkpoint with respect to GBM, as well as a summary of combination therapies with chemotherapy and radiation.
url http://dx.doi.org/10.1155/2016/4683607
work_keys_str_mv AT eileenskim immunecheckpointmodulatorsanemergingantigliomaarmamentarium
AT jenniferekim immunecheckpointmodulatorsanemergingantigliomaarmamentarium
AT miraapatel immunecheckpointmodulatorsanemergingantigliomaarmamentarium
AT antonellamangraviti immunecheckpointmodulatorsanemergingantigliomaarmamentarium
AT jacobruzevick immunecheckpointmodulatorsanemergingantigliomaarmamentarium
AT michaellim immunecheckpointmodulatorsanemergingantigliomaarmamentarium
_version_ 1725746016435568640